Aflibercept and FOLFIRI Therapy -14 day
Indication
00238a
Aflibercept is indicated as second line therapy in combination with irinotecan/5-Fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.
Atezolizumab and Bevacizumab Therapy
Indication
00831a
Atezolizumab in combination with bevacizumab for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Bevacizumab 10 mg/kg –14 days
Indication
00212a
In combination with fluoropyrimidine-based chemotherapy for treatment of adult patients with metastatic carcinoma of the colon or rectum.
Bevacizumab 7.5 mg/kg –21 days
Indication
00214a
In combination with fluoropyrimidine-based chemotherapy for treatment of adult patients with metastatic carcinoma of the colon or rectum.
Bevacizumab 15 mg/kg –21 days
Indication
00215d
In combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.
Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy
Indication
00623a
Treatment of metastatic or unresectable colorectal cancer in patients not suitable for combination chemotherapy with irinotecan or oxaliplatin
Bevacizumab 5mg/kg, 5-Fluorouracil and Folinic Acid Therapy-14 day
Bevacizumab 5mg/kg and FOLFIRI Therapy-14 day
Indication
00449a
Treatment of adult patients with metastatic carcinoma of the colon or rectum.
Bevacizumab 5mg/kg and modified FOLFOX-6 Therapy-14 day
Indication
00446a
Treatment of adult patients with metastatic carcinoma of the colon or rectum.
Bevacizumab 5mg/kg and FOLFOXIRI -14 day
Capecitabine Monotherapy
Indication
00216b
Treatment of metastatic colorectal cancer.
00216c
Adjuvant treatment of patients following surgery of stage III colon cancer.
00216d*
Adjuvant treatment of patients following surgery of stage II colon cancer.
00216e*
Adjuvant treatment of patients with metastatic colorectal cancer following complete resection.
Capecitabine 825mg/m2 and RT–7 day
Capecitabine and RT–7 day
Capecitabine and Temozolomide Therapy
Indication
00505a
Treatment of patients with locally advanced or metastatic neuroendocrine tumours of the pancreas.
Capecitabine and Oxaliplatin Therapy (XELOX)
Indication
00321a
Adjuvant treatment of stage III (Dukes C) colon cancer after complete resection of the primary tumour.
00321b
Treatment of advanced or metastatic colorectal cancer.
00321c
Adjuvant Stage II/III gastric adenocarcinoma post D2 gastrectomy.
CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks
Indication
00422a
Preoperative chemoradiation treatment of oesophageal and gastro-oesophageal junction carcinomas.
Cetuximab Therapy- 7 days
Indication
00207a
Treatment of patients with epidermal growth factor receptor (EGFR)-expressing RAS wild-type metastatic colorectal cancer (mCRC)
Cetuximab Therapy-14 days
Indication
00732a
As monotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing RAS wild-type metastatic colorectal cancer (mCRC) in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan
Cetuximab (7 days) and Irinotecan (14 days ) Therapy
Indication
00330a
Second line therapy for metastatic colorectal cancer with non-mutated (wild type) RAS after failure of or contraindication to oxaliplatin based therapy.
Cetuximab (14 days) and Irinotecan (14 days ) Therapy
Indication
00331a
Second line therapy for metastatic colorectal cancer with non-mutated (wild type) RAS after failure of or contraindication to oxaliplatin based therapy.
Cetuximab and FOLFOX-4 Therapy
Cetuximab and FOLFOX-6 (modified) Therapy
Cetuximab (7 days) and FOLFIRI (14 days)
Cetuximab (14 days) and FOLFIRI (14 days) Therapy
CISplatin and Capecitabine Adjuvant Chemoradiation Therapy
Indication
00473a
Adjuvant treatment of adult patients with resected gastric cancer stage IIA or higher and no distant metastases.
CISplatin, 5-Fluorouracil and Radiation Therapy
CISplatin 75mg/m2 and 5-Fluorouracil Chemoradiation Therapy-Herskovic Regimen
Indication
00460a
Locally advanced squamous or adenocarcinoma of the oesophagus not suitable for surgery.
Teysuno® and CISplatin - 28 day cycle
Indication
00235a
Treatment of advanced gastric cancer when given in combination with cisplatin.
DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle
Indication
00203d
Advanced or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction in patients who have progressed during or within 6 months after treatment with a platinum-fluoropyrimidine combination
DOXOrubicin 60mg/m2 Therapy
Indication
00386a
Treatment of unresectable or metastatic hepatocellular carcinoma not suitable for treatment with regional therapies.
Durvalumab 1500mg, Gemcitabine (1000mg/m2) and CISplatin (25mg/m2) Therapy
Indication
00897a
Durvalumab in combination with gemcitabine and CISplatin for the first line treatment of adults with unresectable or metastatic biliary tract cancer (BTC).
epiRUBicin, CISplatin and 5-Fluorouracil (ECF) Therapy - 21 day
Indication
00240a
Metastatic or locally advanced (unresectable) gastric adenocarcinoma.
00240b
Metastatic or locally advanced (unresectable) esophagogastric junction adenocarcinoma.
00240c
Metastatic or locally advanced (unresectable) oesophageal adenocarcinoma.
00240d
Perioperative treatment of resectable gastric adenocarcinoma.
00240e
Perioperative treatment of resectable gastroesophageal junction adenocarcinoma.
00240f
Perioperative treatment of resectable lower oesophagus adenocarcinoma.
epiRUBicin, CISplatin and Capecitabine (ECX) Therapy
Indication
00380a
Perioperative treatment of resectable gastric adenocarcinoma.
00380b
Perioperative treatment of resectable gastrioesophageal junction adenocarcainoma.
00380c
Perioperative treatment of resectable lower oesophagus adenocarcinoma.
00380d
Palliative therapy for metastatic or locally advanced gastric adenocarcinoma.
00380e
Palliative therapy for metastatic or locally advanced oesphagogastric adenoccarcinoma.
epiRUBicin Oxaliplatin and 5-Fluorouracil (EOF) -21 day
Indication
00429a
Locally advanced or metastatic gastric carcinoma
00429b
Locally advanced or metastatic oesophageal carcinoma
00429c
Locally advanced or metastatic gastroesophageal carcinoma
epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy - 21 day
Indication
00239a
Locally advanced or metastatic gastric carcinoma.
00239b
Locally advanced or metastatic oesophageal carcinoma.
00239c
Locally advanced or metastatic gastroesophageal carcinoma.
Everolimus Monotherapy
Indication
00320b
Treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.
00320c
The treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal origin in adults with progressive disease
FLOT Therapy-14 day
Indication
00344a
Treatment of locally advanced (≥T2) and/or nodal positive (N+) resectable gastric adenocarcinoma
00344b
Treatment of locally advanced ((≥T2) and/or nodal positive (N+) resectable adenocarcinoma of the oesophagogastreal junction
FLOX Therapy
Indication
00486a
Adjuvant treatment of stage II or III colon cancer after complete resection of primary tumour
FOLFIRI Therapy-14 day
Indication
00227a
Treatment of patients with advanced colorectal cancer.
00227b
Treatment of patients with metastatic oesophageal carcinoma.
00227c
Second line treatment of patients with locally advanced metastatic pancreatic carcinoma
FOLFOX- 4 Therapy-14 day
Indication
00210a
Adjuvant treatment of stage II and stage III colon cancer after complete resection of primary tumour.
00210b
Metastatic colorectal carcinoma
Modified FOLFOX- 6 Therapy-14 day
Indication
00209a
Adjuvant treatment of stage II or III colon cancer after complete resection of primary tumour
00209b
Metastatic colorectal carcinoma
00209c
Advanced or metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
Modified FOLFOX-6 Chemoradiation Therapy-14 day
Indication
00509a
Definitive squamous cell carcinoma (SCC) or adenocarcinoma of the oesophagus in combination in patients for whom a CISplatin based regimen is contraindicated.
FOLFOXIRI Therapy
FOLFIRINOX Therapy
FOLFIRINOX Modified Therapy
Indication
00515a
Adjuvant treatment of pancreatic ductal adenocarcinoma
00515b
Metastatic pancreatic cancer
FOLFIRINOX Therapy - (Rectal Carcinoma)
5-Fluorouracil and Folinic acid Therapy-14 day
Indication
00660a
Adjuvant treatment of colorectal carcinoma
00660b
Locally advanced, locally recurrent or metastatic colorectal adenocarcinoma, not curable with surgery or radiation
5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy
5-Fluorouracil 225mg/m2/day and Radiotherapy (RT)-Continuous infusion (7day)
Fruquintinib Monotherapy
Indication
00890a
As monotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib
Gemcitabine 1000mg/m2Monotherapy-28 day
Gemcitabine 1000mg/m2Monotherapy- 56 day
Indication
00283a
Treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.
Gemcitabine (400mg/m2) and RT therapy
Gemcitabine (600mg/m2) and RT therapy
Indication
00559a
Treatment of patients with localized unresectable adenocarcinoma of the pancreas
Gemcitabine (1000mg/m2) and RT therapy
Gemcitabine (1000mg/m2) and Capecitabine (650mg/m2) Therapy- 21 day
Indication
00384a
Locally advanced or metastatic pancreatic carcinoma.
00384b
Locally advanced biliary tree carcinoma.
Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy- 28 day
Indication
00524a
Adjuvant treatment of pancreatic adenocarcinoma after macroscopic complete resection.
Gemcitabine (1000mg/m2) and CISplatin (25mg/m2)Therapy-21 day
Indication
00383a
Locally advanced or metastatic pancreatic carcinoma
00383b
Locally advanced or metastatic biliary tree carcinoma.
Irinotecan Monotherapy - 21days
Indication
00213a
Treatment of patients with advanced colorectal cancer as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.
Irinotecan 150mg/m2 Monotherapy – 28 days
Indication
00654a
Second line therapy for advanced gastric cancer refractory to treatment with fluoropyrimidine plus platinum
Ivosidenib Therapy
Indication
00901a
As monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated with at least one prior line of systemic therapy.
Lenvatinib – HCC Therapy
Indication
00644a
As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy
Lutetium (177Lu) oxodotreotide (Lutathera®) Therapy
Indication
00642a
Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive- gastroenteropancreatic neuroendocrine tumours (GEP- NETs) in adults.
mitoMYcin and Capecitabine Chemoradiation Therapy
nab-PACLitaxel and Gemcitabine Therapy– 28 day
Indication
00256a
nab-PACLitaxel in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
Nivolumab and FOLFOX-6 Modified Therapy
Indication
00844a
Nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell programmed death ligand 1 (PD-L1) expression ≥1%.
00844b
Nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for first line treatment of adult patients with HER-2 negative advanced or metastatic gastric cancer (GC), gastroesophageal junction cancer (GEJC) or esophageal adenocarcinoma (EAC), whose tumours express PD-L1 (CPS) ≥5.
Nivolumab 28 day, CISplatin 80mg/m2 and 5-Fluorouracil infusional Therapy
Indication
00832a
Nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell programmed death ligand 1 (PD-L1) expression ≥1%.
Nivolumab 14 day, CISplatin 80mg/m2 and 5-Fluorouracil infusional Therapy
Indication
00816a
Nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell programmed death ligand 1 (PD-L1) expression ≥1%.
Nivolumab 3mg/kg with Ipilimumab 1mg/kg Therapy
Indication
00551c
Nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-H mCRC) after prior fluoropyrimidine-based combination chemotherapy.
Nivolumab 240mg and Ipilimumab 1mg/kg Therapy
Indication
00900a
Nivolumab in combination with ipilimumab for the first-line treatment of adult patient with unresectable or metastatic mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC).
Nivolumab Monotherapy- 14 day
Indication
00483g
As monotherapy for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction (GEJ) cancer who have residual pathologic disease following prior neo-adjuvant chemo-radiotherapy.
Nivolumab Monotherapy- 28 day
Indication
00484g
As monotherapy for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction (GEJ) cancer who have residual pathologic disease following prior neo-adjuvant chemo-radiotherapy.
Nivolumab and XELOX Therapy
Indication
00843a
Nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for first line treatment of adult patients with HER-2 negative advanced or metastatic gastric cancer (GC), gastroesophageal junction cancer (GEJC) or esophageal adenocarcinoma (EAC), whose tumours express PD-L1 (CPS) ≥5.
Olaparib (Tablet) Monotherapy
Indication
00588i
As monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.
PACLitaxel 80mg/m2 Day 1, 8, 15 Monotherapy-28 Day
Panitumumab 6mg/kg Therapy
Indication
00225c
Treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) As monotherapy after failure of fluorpyridine, oxaliplatin, and irinotecan containing chemotherapy regimens.
Panitumumab 6mg/kg and FOLFIRI Therapy-14 day
Indication
00448a
First line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC)
00448b
Second line treatment of adult patients with wild-type RAS mCRC who have received first-line fluorpyridine–based chemotherapy (excluding irinotecan)
Panitumumab 6mg/kg and modified FOLFOX-6 Therapy-14 day
Indication
00447a
First line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC)
Pemigatinib Therapy
Indication
00889a
As monotherapy for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Pembrolizumab 200mg Monotherapy
Indication
00455k
First-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in adults
Pembrolizumab 400mg Monotherapy
Indication
00558k
First-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in adults
Pembrolizumab 200mg, CISplatin 80mg/m2 and 5- Fluorouracil Infusional Therapy
Indication
00739
Pembrolizumab in combination with platinum and fluoropyrimidinebased chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS≥10
Pembrolizumab and FOLFOX-6 Modified Therapy
Indication
00839a
Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS≥10.
QUASAR (Modified) 5-Fluorouracil (370mg/m2) and Folinic Acid (50mg) weekly
Indication
00428a
Treatment of metastatic colorectal cancer.
00428b
Adjuvant treatment of colorectal cancer.
Regorafenib Monotherapy
Indication
00244a
Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.
Roswell Park Modified (5-Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6)
Indication
00427a
Treatment of metastatic colorectal cancer.
00427b
Adjuvant treatment of colorectal cancer.
SORAfenib Therapy
Tislelizumab and CAPOX Therapy
Indication
00924
First-line treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (OSCC) whose tumours express programmed death-ligand (PD-L1) with a tumour area positivity (TAP) score ≥ 5%
Tislelizumab and FOLFOX-6 Modified Therapy
Indication
00925
First-line treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (OSCC) whose tumours express programmed death-ligand (PD-L1) with a tumour area positivity (TAP) score ≥ 5%
Trastuzumab, 5-Fluorouracil and CISplatin Therapy-21days
Indication
00502a
Treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
Trastuzumab and FOLFOX-6 Modified Therapy-14 day
Indication
00704a
Treatment of adult patients with HER2 positive metastatic gastric or gastroesophageal junction cancer
Tremelimumab and Durvalumab Therapy
Indication
00926a
Tremelimumab in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC)
Trifluridine and Tipracil (Lonsurf®)Therapy
Indication
00382a
Treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.